Novel Molecular Markers in Glioblastoma—Benefits of Liquid Biopsy
<b>: </b>Glioblastoma is a primary Central Nervous System (CNS) malignancy with poor survival. Treatment options are scarce and despite the extremely heterogeneous nature of the disease, clinicians lack prognostic and predictive markers to characterize patients with different outcomes. C...
Main Authors: | Zsuzsanna Birkó, Bálint Nagy, Álmos Klekner, József Virga |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/20/7522 |
Similar Items
-
Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity
by: Gábor Hutóczki, et al.
Published: (2021-09-01) -
Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients
by: Dóra Géczi, et al.
Published: (2021-05-01) -
Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges
by: Ander Saenz-Antoñanzas, et al.
Published: (2019-07-01) -
Graphene-Based Strategies in Liquid Biopsy and in Viral Diseases Diagnosis
by: Annalaura Cordaro, et al.
Published: (2020-05-01) -
Epigenetic Landscape of Liquid Biopsy in Colorectal Cancer
by: Aitor Rodriguez-Casanova, et al.
Published: (2021-02-01)